JP2014532623A5 - - Google Patents

Download PDF

Info

Publication number
JP2014532623A5
JP2014532623A5 JP2014537142A JP2014537142A JP2014532623A5 JP 2014532623 A5 JP2014532623 A5 JP 2014532623A5 JP 2014537142 A JP2014537142 A JP 2014537142A JP 2014537142 A JP2014537142 A JP 2014537142A JP 2014532623 A5 JP2014532623 A5 JP 2014532623A5
Authority
JP
Japan
Prior art keywords
composition
liposomes
lyophilization
reconstitution
liposome
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014537142A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014532623A (ja
JP6133308B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2012/060293 external-priority patent/WO2013059133A1/en
Publication of JP2014532623A publication Critical patent/JP2014532623A/ja
Publication of JP2014532623A5 publication Critical patent/JP2014532623A5/ja
Application granted granted Critical
Publication of JP6133308B2 publication Critical patent/JP6133308B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014537142A 2011-10-21 2012-10-15 凍結乾燥リポソーム Active JP6133308B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161550047P 2011-10-21 2011-10-21
US61/550,047 2011-10-21
PCT/US2012/060293 WO2013059133A1 (en) 2011-10-21 2012-10-15 Lyophilized liposomes

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017074348A Division JP6359717B2 (ja) 2011-10-21 2017-04-04 凍結乾燥リポソーム

Publications (3)

Publication Number Publication Date
JP2014532623A JP2014532623A (ja) 2014-12-08
JP2014532623A5 true JP2014532623A5 (enExample) 2015-10-15
JP6133308B2 JP6133308B2 (ja) 2017-05-24

Family

ID=48141268

Family Applications (7)

Application Number Title Priority Date Filing Date
JP2014537142A Active JP6133308B2 (ja) 2011-10-21 2012-10-15 凍結乾燥リポソーム
JP2017074348A Active JP6359717B2 (ja) 2011-10-21 2017-04-04 凍結乾燥リポソーム
JP2018095127A Active JP6592556B2 (ja) 2011-10-21 2018-05-17 凍結乾燥リポソーム
JP2019172314A Pending JP2020007367A (ja) 2011-10-21 2019-09-20 凍結乾燥リポソーム
JP2021196626A Active JP7476161B2 (ja) 2011-10-21 2021-12-03 凍結乾燥リポソーム
JP2024000732A Pending JP2024045183A (ja) 2011-10-21 2024-01-05 凍結乾燥リポソーム
JP2026042662A Pending JP2026102777A (ja) 2011-10-21 2026-03-17 凍結乾燥リポソーム

Family Applications After (6)

Application Number Title Priority Date Filing Date
JP2017074348A Active JP6359717B2 (ja) 2011-10-21 2017-04-04 凍結乾燥リポソーム
JP2018095127A Active JP6592556B2 (ja) 2011-10-21 2018-05-17 凍結乾燥リポソーム
JP2019172314A Pending JP2020007367A (ja) 2011-10-21 2019-09-20 凍結乾燥リポソーム
JP2021196626A Active JP7476161B2 (ja) 2011-10-21 2021-12-03 凍結乾燥リポソーム
JP2024000732A Pending JP2024045183A (ja) 2011-10-21 2024-01-05 凍結乾燥リポソーム
JP2026042662A Pending JP2026102777A (ja) 2011-10-21 2026-03-17 凍結乾燥リポソーム

Country Status (22)

Country Link
US (5) US10028912B2 (enExample)
EP (2) EP2768484B1 (enExample)
JP (7) JP6133308B2 (enExample)
KR (5) KR102284689B1 (enExample)
CN (2) CN104114156A (enExample)
AU (1) AU2012326370C9 (enExample)
BR (1) BR112014009305B1 (enExample)
CA (1) CA2852777C (enExample)
DK (1) DK2768484T3 (enExample)
ES (1) ES2750368T3 (enExample)
FR (1) FR19C1063I2 (enExample)
HR (1) HRP20191683T1 (enExample)
HU (2) HUE045978T2 (enExample)
IL (1) IL232161B (enExample)
LU (1) LUC00135I2 (enExample)
NL (1) NL301016I2 (enExample)
NO (1) NO2019041I1 (enExample)
PL (1) PL2768484T3 (enExample)
PT (1) PT2768484T (enExample)
RU (1) RU2648753C2 (enExample)
SI (1) SI2768484T1 (enExample)
WO (1) WO2013059133A1 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2768484T (pt) * 2011-10-21 2019-10-28 Jazz Pharmaceuticals Res Llc Lipossomas liofilizados
DK3033102T4 (da) 2013-08-13 2024-02-26 Univ Northwestern Peptidkonjugerede partikler
WO2016033384A1 (en) 2014-08-28 2016-03-03 The General Hospital Corporation Injectable slurries and methods of manufacturing and using the same
US11471401B2 (en) 2014-08-28 2022-10-18 The General Hospital Corporation Injectable slurries and methods of manufacturing the same
US11504322B2 (en) 2014-08-28 2022-11-22 The General Hospital Corporation Injectable slurries and methods of manufacturing the same
KR20180016347A (ko) * 2015-04-13 2018-02-14 파운테인 테크놀로지스 인터내셔널, 엘엘씨 초-소형 지질 구조체의 생산을 위한 단일-단계 방법
CN113679689B (zh) 2015-07-22 2023-09-01 日东电工株式会社 用于纳米粒冷冻干燥物形式的组合物及方法
BR112018009463A8 (pt) * 2015-11-11 2019-02-26 Celator Pharmaceuticals Inc ensaios e métodos para selecionar um regime de tratamento para um sujeito com leucemia
DK3419572T3 (da) 2016-02-26 2026-06-29 Massachusetts Gen Hospital Systemer og fremgangsmåder til fremstilling og administrering af medicinsk isopslæmning
US11504347B1 (en) 2016-07-22 2022-11-22 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
UY37341A (es) 2016-07-22 2017-11-30 Flamel Ireland Ltd Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada
US11986451B1 (en) 2016-07-22 2024-05-21 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602512B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12186296B1 (en) 2016-07-22 2025-01-07 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602513B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12478604B1 (en) 2016-07-22 2025-11-25 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US20200230057A1 (en) * 2017-07-10 2020-07-23 Immunovaccine Technologies Inc. Pharmaceutical Compositions, Methods for Preparation using Lipid Vesicle Particles of Defined Size, and Uses Thereof
US20240252522A1 (en) 2018-09-25 2024-08-01 Celator Pharmaceuticals, Inc. Low-intensity treatment of hematological disorders
BR112021013766A2 (pt) 2019-03-01 2021-09-21 Flamel Ireland Limited Composições de gama-hidroxibutirato com farmacocinética melhorada no estado alimentado
BR112021026480A2 (pt) * 2019-06-28 2022-02-08 Univ Texas Método para reconstituir anamicina, método para preparar uma dose eficaz de uma formulação lipossômica reconstituída de anamicina e método para tratar câncer
US20220273569A1 (en) * 2019-07-24 2022-09-01 The General Hospital Corporation Methods of creating a substance with different freezing points by encapsulation
US11980636B2 (en) 2020-11-18 2024-05-14 Jazz Pharmaceuticals Ireland Limited Treatment of hematological disorders
US11583510B1 (en) 2022-02-07 2023-02-21 Flamel Ireland Limited Methods of administering gamma hydroxybutyrate formulations after a high-fat meal
US11779557B1 (en) 2022-02-07 2023-10-10 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
CN115252563B (zh) * 2022-06-24 2024-07-12 石药集团中奇制药技术(石家庄)有限公司 一种柔红霉素阿糖胞苷脂质体冻干品的制备方法
CN116003493B (zh) * 2022-12-16 2025-02-28 常州金远药业制造有限公司 一种二价铜离子及阿糖胞苷的回收方法

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4880635B1 (en) * 1984-08-08 1996-07-02 Liposome Company Dehydrated liposomes
US5077056A (en) 1984-08-08 1991-12-31 The Liposome Company, Inc. Encapsulation of antineoplastic agents in liposomes
EP0208764A4 (en) 1985-01-11 1987-10-08 Univ California METHOD FOR PRESERVING LIPOSOMES.
CA1256372A (en) 1985-04-11 1989-06-27 Koichiro Miyazima Process for producing liposome composition
US4927571A (en) 1987-05-18 1990-05-22 Liposome Technology, Inc. Preparation of injectable doxorubicin/liposome suspension
US4915951A (en) 1987-12-03 1990-04-10 California Institute Of Technology Cryoprotective reagent
DE68916439T2 (de) * 1988-10-05 1994-10-20 Vestar Inc Verfahren zur herstellung von liposomen mit verbesserter stabilität während des trocknens.
US5049392A (en) * 1989-01-18 1991-09-17 The Liposome Company, Inc. Osmotically dependent vesicles
DE69720979T2 (de) * 1996-02-19 2004-02-26 Amersham Health As Thermostabilisiertes kontrastmittel
IT1289938B1 (it) 1997-02-20 1998-10-19 Angelini Ricerche Spa Preparazione farmaceutica comprendente liposomi liofilizzati in cui e' incapsulato un principio attivo altamente insolubile in acqua e
GB9813100D0 (en) 1998-06-18 1998-08-19 Secr Defence Method of forming liposomes
WO2001005372A2 (en) 1999-07-16 2001-01-25 Alza Corporation A liposome composition having resistance to freeze/thaw damage
US6984395B2 (en) * 2001-04-11 2006-01-10 Qlt, Inc. Drug delivery system for hydrophobic drugs
US7850990B2 (en) 2001-10-03 2010-12-14 Celator Pharmaceuticals, Inc. Compositions for delivery of drug combinations
EP1432403B1 (en) 2001-10-03 2010-07-28 Celator Pharmaceuticals, Inc. Liposome loading with metal ions
US20050118250A1 (en) * 2001-11-13 2005-06-02 Paul Tardi Lipid carrier compositions with enhanced blood stability
DE60222580T2 (de) 2001-11-13 2008-06-12 Celator Pharmaceuticals, Inc. Lipidträgerzusammensetzungen und verfahren zur verbesserten wirkstoffzurückhaltung
JP2006508126A (ja) * 2002-11-06 2006-03-09 アザヤ セラピューティクス インコーポレイティッド 薬学的製剤のタンパク質安定化されたリポソーム製剤
EP1608337A2 (en) * 2003-04-02 2005-12-28 Celator Technologies Inc. Combination compositions of camptothecins and fluoropyrimidines
JP4972545B2 (ja) 2004-04-22 2012-07-11 セレーター ファーマスーティカルズ、インク. アントラサイクリン系薬剤及びシチジンアナログのリポソーム製剤
US7893338B2 (en) * 2004-07-15 2011-02-22 Creative Technology Ltd Method of composing music on a handheld device
CA2584583A1 (en) * 2004-10-28 2006-05-11 Alza Corporation Lyophilized liposome formulations and method
AU2005304914B2 (en) * 2004-11-05 2012-02-16 Tekmira Pharmaceuticals Corporation Compositions and methods for stabilizing liposomal camptothecin formulations
EP1817005A1 (en) 2004-11-18 2007-08-15 Celator Pharmaceuticals, Inc. Method for loading multiple agents into delivery vehicles
EP1951239A2 (en) 2005-10-25 2008-08-06 Celator Pharmaceuticals, Inc. Fixed ratio drug combination treatments for solid tumors
US20090148506A1 (en) 2005-12-22 2009-06-11 Awa Dicko Liposomal formulations comprising secondary and tertiary amines and methods for preparing thereof
PT2120568T (pt) * 2007-02-16 2017-12-04 Celator Pharmaceuticals Inc Rácios de fármacos fixados para tratamento de cancros hematopoiéticos e desordens proliferativas
WO2009097011A1 (en) 2007-08-17 2009-08-06 Celator Pharmaceuticals, Inc. Improved platinum drug formulations
CN101878024B (zh) 2007-11-28 2014-04-09 塞拉特药物股份有限公司 改良的紫杉烷递送系统
WO2010043050A1 (en) 2008-10-16 2010-04-22 Celator Pharmaceuticals Corporation Combinations of a liposomal water-soluble camptothecin with cetuximab or bevacizumab
PT2508170E (pt) 2009-12-03 2015-10-16 Shanghai Hengrui Pharm Co Ltd Lipossoma de irinotecano ou o seu cloridrato e seu método de preparação
WO2011092708A2 (en) * 2010-02-01 2011-08-04 Yissum Research Development Company Of The Hebrew University Of Jerusalem, Ltd. Liposomes comprising amphipathic drugs and method for their preparation
PT2768484T (pt) * 2011-10-21 2019-10-28 Jazz Pharmaceuticals Res Llc Lipossomas liofilizados

Similar Documents

Publication Publication Date Title
JP2020007367A5 (enExample)
JP2024045183A5 (enExample)
Shao et al. Biomimetic diselenide‐bridged mesoporous organosilica nanoparticles as an X‐ray‐responsive biodegradable carrier for chemo‐immunotherapy
RU2014120475A (ru) Лиофилизированные липосомы
Wang et al. An engineered nanoplatform with tropism toward irradiated glioblastoma augments its radioimmunotherapy efficacy
KR102203555B1 (ko) 입자의 동결건조 또는 동결을 위한 중합체 부형제의 용도
Zhao et al. Remodeling the hepatic fibrotic microenvironment with emerging nanotherapeutics: a comprehensive review
van der Heijden et al. Effects of hyperthermia in neutralising mechanisms of drug resistance in non-muscle-invasive bladder cancer
WO2010039762A3 (en) Pharmaceutical compositions comprising boronic acid compounds
RU2018110333A (ru) Стабильный фармацевтический препарат на основе антитела к pd-1 и его применение в медицине
NZ701915A (en) High-concentration monoclonal antibody formulations
NZ707328A (en) Virus-containing formulation and use thereof
ES2899226T3 (es) Composiciones liofilizadas en superficie específica elevada que comprende el arsénico destinadas a una administración oral en pacientes
JP2008509924A5 (enExample)
JP2011251975A5 (enExample)
WO2012107865A3 (en) Modulation of growth of bifidobacteria using a combination of oligosaccharides found in human milk
WO2016094189A1 (en) Nanoparticle compositions and methods thereof to restore vascular integrity
JP2013532729A5 (enExample)
JP2019521179A5 (enExample)
CN108495619A (zh) 棘霉素制剂及其制备方法和使用方法
Rampersaud et al. Hyperthermia as a treatment for bladder cancer
WO2021228832A1 (en) Red cell extracellular vesicles (rcevs) containing cargoes and methods of use and production thereof
Joshi et al. Liposomes: a promising carrier for respiratory syncytial virus therapeutics
JP2015526463A5 (enExample)
CN109790530A (zh) 治疗癌症的方法